▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #317 by analyst upside · 2026-09-20
MIRA
MIRA Pharmaceuticals, Inc.
Healthcare · Market Cap $35M · P/E 0x
ANALYST PRICE TARGET
+320.5%
implied upside to consensus target
Current Price $0.83
Consensus Target $3.5
Bull Target $3.5
Bear Target $3.5
Analysts Covering 1
ANALYST CONSENSUS - STRONG BUY
Strong Buy
1
Buy
0
Hold
0
Sell
0
52-Week Low $0.6
52-Week High $2.45
YTD Return -44.2%
FUNDAMENTALS
Market Cap $35M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.22
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.6
52-Week High $2.45
Current Price $0.83
Bear Target $3.5
Bull Target $3.5
● Now $0.83 ● Target $3.5
TRADING DATA
Avg Volume 574K
YTD Return -44.2%
Analyst Count 1
Consensus Strong Buy
Upside to Target +320.5%
Last Updated 2026-09-20

ANALYST SUMMARY

MIRA Pharmaceuticals, Inc. (MIRA) is currently trading at $0.83 with a Wall Street consensus price target of $3.5, implying potential upside of 320.5% over the next 12 months. 1 analysts currently cover MIRA, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $3.5, while the most cautious has a target of $3.5.

MIRA operates in the Healthcare sector with a market capitalisation of $35M. The stock is down 44.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.6 – $2.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SPRO +342.5%
Spero Therapeutics, Inc.
$66M · P/E 8.1x · Buy
FBIO +338.2%
Fortress Biotech, Inc.
$84M · P/E 0.9x · Buy
ATNM +195.1%
Actinium Pharmaceuticals, Inc.
$38M · P/E 3.5x · Buy
AZTR +345.4%
Azitra, Inc.
$11M · P/E 8.7x · Underperform
CCLD +237.9%
CareCloud, Inc.
$92M · P/E 31.0x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for MIRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Maxim Group ● Initiated
Buy 2026-09-17 28% win rate (40 calls)
Rodman & Renshaw ● Initiated
Buy 2024-09-30 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →